黄连素联合阿托伐他汀降低脑梗死患者外周血淋巴细胞MIF和MCP-1表达的研究

目的探讨黄连素联合阿托伐他汀对脑梗死患者外周血淋巴细胞巨噬细胞移动抑制因子（macrophage migration inhibitory factor，MIF）和单核细胞趋化蛋白l（monocyte chemoattractant protein-1，MCP-t）表达的影响。方法通过计算机随机编码将120例脑梗死患者随机分为对照组、阿托伐他汀组、黄连素组和联合治疗组4组各30例分别进行治疗，同时抽取120例脑梗死患者外周静脉血10～15ml，分离培养外周血淋巴细胞，将细胞分为对照组、阿托伐他汀组、黄连素组和联合处理组（各30例）分别进行处理。应用实时定量PCR（qRT—PCR）和免疫印迹法检测体外处理的外周血淋巴细胞中MIF和MCP-1的表达水平；应用ELISA法检测临床分组治疗患者血清MIF和MCP-1水平。用qRT－PCR定量分析分离的外周血淋巴细胞中MIF和MCP-1的基因表达水平。结果不论是体外实验数据还是临床应用，检测结果均显示联合处理（治疗）组外周血淋巴细胞中MIF和MCP-1mRNA的表达水平明显低于对照组、阿托伐他汀组和黄连素组（P〈0．05）。结论黄连素联合阿托伐他汀处理能有效地降低脑梗死患者外周血淋巴细胞中MIF和MCP－1的表达。

Berberine combined with atorvastatin can decrease the expression of MIF and MCP-1 of pe- ripheral blood lymphocytes in patients with cerebral infarction

Objective To investigate the effect of berberine combined with atorvastatin on the expressions of macrophage mi- gration inhibitory factor（MIF） and monocyte chemoattractant protein-1 （ MCP-1 ） in peripheral blood lymphocytes in patients with cerebral. Methods Peripheral blood lymphocytes from cerebral infarction patients were isolated and cultured in vitro. The cells were then divided into 4 groups：control group, atorvastatin group, berberine group, and combined group （berberine combined with atorvastatin）. Expressions of MIF and MCP-1 in these cells were analyzed by a quantitative real time-PCR（qRT-PCR） and a Western blot after 4 hours of treatment. For in vivo exploration, 120 patients with cerebral infarction were recruited and randomly divided into control group, atorvastatin group, berberine group, and combined group. At the end of treatment, the levels of plasma MIF and MCP-1 were detected by an enzyme linked immunosorbent assay （ELISA）. In addition, the expressions of MIF and MCP-1 in peripheral blood lymphocytes in these.patients were also analyzed by the qRT-PCR and the Western blot. Results The expression levels of MIF and MCP-1 in the combined group in both experiments in vitro and in clinical practice were markedly down-regulated compared with those in the control, atorvastatin and berberine groups. Conclusion Berberine combined with atorvastatin may effectively decrease the levels of MIF and MCP- 1 expression in peripheral blood lymphocytes in patients with cerebral infarction.